高龄心血管病患者中心血管危险因子的性别差异:PROTEGER研究

2012-01-01 MedSci原创 MedSci原创

    回顾既往的临床研究结果,我们发现男性和女性虽然有着相似的心血管危险因子,但这些危险因子所导致心血管疾病在男女之间却并不相同。例如,男性更容易患有冠心病及心力衰竭,而女性则更易发生高血压和糖尿病。这提示我们,是否这些心血管危险因子在致病机制方面存在着一定的性别差异。此外,女性发生心血管疾病的时间往往要比男性晚10年左右,但在绝经后,女性的心血管疾病的患病率和死亡

    回顾既往的临床研究结果,我们发现男性和女性虽然有着相似的心血管危险因子,但这些危险因子所导致心血管疾病在男女之间却并不相同。例如,男性更容易患有冠心病及心力衰竭,而女性则更易发生高血压糖尿病。这提示我们,是否这些心血管危险因子在致病机制方面存在着一定的性别差异。此外,女性发生心血管疾病的时间往往要比男性晚10年左右,但在绝经后,女性的心血管疾病的患病率和死亡率会随着年龄的增长而逐渐上升。这往往被认为是由于失去了雌激素的心血管保护作用而引起的。如果真是如此,那么,在高龄的心血管疾病患者中,在绝经多年以后,心血管危险因子对死亡的预测价值应该可以在男女间表现出一致性的结果。为了验证这一假设,我们在PROTEGER人群中展开了有关心血管危险因子性别差异的研究。

 

    我们从法国巴黎的Charles Foix和Emile Roux两所医院的老年科募集了331名70岁以上的心血管疾病患者(其中86名男性,平均年龄86.8岁)。在经过了平均378天的随访,有110例患者死亡。我们利用超声技术检测了患者的颈动脉内中膜厚度(IMT),左心房内径(LAD),舒张早期二尖瓣血流的减速时间(DTE)和左心室射血分数(LVEF);利用心电图技术判断了患者是否患有心律失常;利用平面张力检测仪器测量了患者的脉搏波传导速度(PWV);利用常规的方法测量了患者的其它心血管危险因子(包括血压、年龄、体重指数、吸烟、血脂、血糖);同时研究这些危险因子与全因死亡之间的关系。结果发现,在完全矫正的模型中,我们发现,左心房内径增大(HR=2.24 per 1-SD; 95% CI: 1.23-4.09),左心室射血分数减少(LVEF,HR=0.60 per 1-SD; 95% CI: 0.38-0.96),总胆固醇与高密度脂蛋白的比值增加(HR=1.99 per 1-SD; 95% CI: 1.05-3.78)是男性患者全因死亡的显著预测因子;而在女性患者中,心律失常(HR=2.47; 95% CI: 1.28-4.78),血糖增高(HR=1.32 per 1-SD; 95% CI: 1.06-1.64),体重指数下降(HR=0.60 per 1-SD; 95% CI: 0.44-0.83)则可显著地预测全因死亡。

结论:

    即使是在高龄的心血管疾病患者中,在女性绝经约20年以后,心血管危险因子在全因死亡的预测方面仍存在着显著的性别差异,并表现出与较年轻的人群相似的结果。该文发表于国际心血管杂志,2010年SCI影响因子6.8分(Int J Cardiol. 2011)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
    2012-02-14 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
    2012-01-03 xlysu
  6. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]
    2012-01-03 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=2021451, encodeId=16b220214512d, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Feb 14 00:43:00 CST 2012, time=2012-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993506, encodeId=7c7d1993506d0, content=<a href='/topic/show?id=09ed221839b' target=_blank style='color:#2F92EE;'>#中心血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22183, encryptionId=09ed221839b, topicName=中心血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Mon Jan 30 23:43:00 CST 2012, time=2012-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1644339, encodeId=e3ac1644339b9, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Wed Oct 17 08:43:00 CST 2012, time=2012-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1922258, encodeId=9f6e1922258b4, content=<a href='/topic/show?id=86fd36e769e' target=_blank style='color:#2F92EE;'>#危险因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36776, encryptionId=86fd36e769e, topicName=危险因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue May 29 00:43:00 CST 2012, time=2012-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416012, encodeId=4a7c141601213, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601655, encodeId=a7dc16016553b, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629727, encodeId=cadd1629e27c0, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Tue Jan 03 01:43:00 CST 2012, time=2012-01-03, status=1, ipAttribution=)]

相关资讯

2011 AHA之右心系统进展

者:同济大学附属上海市肺科医院 荆志成 来源:中国医学论坛报   美国心脏学会(AHA)年会释放出的信息量很大,仅右心领域进展就令人目不暇接。闲暇之时笔者不禁忧虑:当前我国心血管领域原创性理论和技术研究显得不足,操作例数往往是国内学术界“比拼”项目,对科学进步贡献最大因素——革命性的新理论和新技术——常被忽略。客观、设计良好的科学研究才是推动国家科技进步的原动力!   近半数国际肺动脉高

美国心血管二级预防指南更新

 美国心脏学会(AHA)/美国心脏病学会基金会(ACCF)冠脉和其他动脉粥样硬化性血管病患者二级预防和危险降低治疗2011更新   自从2006年美国心脏学会(AHA)/美国心脏病学会基金会(ACCF)《冠脉和其他动脉粥样硬化性血管病患者二级预防指南》更新后,临床试验证据不断涌现,进一步支持在已有冠脉和其他动脉粥样硬化性血管病患者包括外周动脉疾病、动脉粥样硬化性主动脉疾病和颈动脉病中强化降低危险

综述:GDF-15在心血管疾病中的研究

徐昕晔, 李子健, 高炜 北京大学第三医院心内科 GDF-15是转化生长因子β超家族的一员,其他名称还包括PTGF-h, PLAB, GDF15, PDF, NAG-1,和 PL74。正常情况下,GDF-15仅在少量组织表达,如胎盘和中枢神经系统;在其他组织如结肠、肾脏和前列腺有少量表达1。但是当肝脏、肾脏、心脏和肺等器官出现损伤时,GDF-15在上述器官的表达就会明显增加。GDF-15参与了

总结:转录辅助活化因子(PGC-1)与心血管疾病

PGC-1是一类过氧化酶增殖激活受体(PPARγ)的转录辅助活化因子(Transcriptional Coactivators)。主要有PGC-1α、PGC-1β和PRC(PGC-Related Coactivators)三个成员。它们可以与体内各种核受体(如PPARγ、ER、TR、GR等)和非核受体(SRRBP、NRF、FOXO1、 Sox9等)的多种转录因子结合、调节各种基因的转录和表达。在体

空气污染是心血管疾病的危险因子研究

一般认为高血脂、高血压、高血糖、高凝状态是心脑血管病最重要、最直接的危险因子,所谓“Cardiomatabolic Risk Factors”。近年来的研究证明空气污染(Air Pollution),亦是心血管病发病和死亡最重要的危险因子之一。它不仅可以引起血管内皮和血管损伤,促进血栓形成,还可以诱发动脉粥样硬化、心律失常、心肌肥厚、心肌梗塞等多种心血管病,而且还是诱发心脏猝死和急性冠状综合征最重

综述:MicroRNA在心血管疾病诊疗中的研究进展

徐明 北医三院心内科 近年来MicroRNA(miRNA)一直是医学生物学研究的热点。它作为一类非编码的小RNA,参与30-50%基因的转录和表达调控[1, 2],因此人体的众多生命活动和疾病的发病发生、发展都与miRNA的变化密不可分。miRNA的作用因细胞特异性和目标mRNA的不同而异,miRNA可以通过影响细胞的发育、分裂、增殖、凋亡、代谢、再生、可塑性等表型的变化,参与疾病的损伤与修复过